Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Trading Down 13.3%

Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) was down 13.3% on Wednesday . The company traded as low as $0.00 and last traded at $0.00, approximately 2,732 shares were traded during mid-day trading. A decline of 70% from the average daily volume of 8,983 shares. The stock had previously closed at $0.00.

About Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

EPIRUS Biopharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis.

Featured Story: Profit Margin

Receive News & Ratings for Epirus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.